Gut Microbiota in Metabolic Surgery
The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study
Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Danxia Yu, PhD
- Phone Number: 615-936-7389
- Email: danxia.yu@vumc.org
Study Contact Backup
- Name: Charles R Flynn, PhD
- Phone Number: 615-343-8329
- Email: robb.flynn@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt_University MC
-
Contact:
- Britt Biesinger, MPH
- Phone Number: 615-421-8055
- Email: britt.t.biesinger@vumc.org
-
Contact:
- Danxia Yu, PhD
- Phone Number: 6159367389
- Email: danxia.yu@vumc.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
We plan to enroll 300 patients who undergo metabolic surgery at the Vanderbilt University Medical Center and follow them up to 10 years after surgery
Description
Inclusion Criteria:
- Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center
- Have a history of type 2 diabetes, hypertension, or dyslipidemia
- Be able and willing to provide personal information and biological samples needed for the study
Exclusion Criteria:
- Prior gastric operations
- A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis
- Chemotherapy or radiotherapy for cancer within 2 years
- Current inflammatory bowel disease or celiac disease
- Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimated 10-year risk of atherosclerotic cardiovascular disease
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
The 10-year risk of atherosclerotic cardiovascular disease based on the American College of Cardiology/American Heart Association pooled cohort equations, incorporating age, sex, race, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, hypertension status, and smoking |
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycated hemoglobin
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
|
|
Blood pressure
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
|
|
Blood cholesterol
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Total, low-density, and high-density lipoprotein cholesterol |
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
|
Blood inflammatory proteins
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
high-sensitivity C-reactive protein |
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Overweight
- Lipid Metabolism Disorders
- Obesity
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Hypertension
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Dyslipidemias
- Obesity, Morbid
- Therapeutics
- Surgical Procedures, Operative
- Bariatrics
- Obesity Management
- Bariatric Surgery
Other Study ID Numbers
Other Study ID Numbers
- VUMC_IRB#201652
- R01DK126721 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.